ArticleJournal of experimental & clinical cancer research : CR2008
NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues.
Article in Journal of experimental & clinical cancer research : CR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 91 citations in OpenAlex.
- Article
- The molecular mechanism of NF-κB dysregulation across different subtypes of renal cell carcinoma.Journal of advanced research · 2025Review
- Decoding iron deficiency in cancer: mechanisms, immune modulation, and therapeutic potential.Frontiers in nutrition · 2025Review
- Common molecular links and therapeutic insights between type 2 diabetes and kidney cancer.PloS one · 2025Article
- Deciphering the tumour microenvironment of clear cell renal cell carcinoma: Prognostic insights from programmed death genes using machine learning.Journal of cellular and molecular medicine · 2024Article
- NF-κB in biology and targeted therapy: new insights and translational implications.Signal transduction and targeted therapy · 2024Review
- Role of non-coding RNAs in neuroblastoma.Cancer gene therapy · 2023Review
- Casein Kinase 2 Alpha Inhibition Protects against Sepsis-Induced Acute Kidney Injury.International journal of molecular sciences · 2023Article
- Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.Nature communications · 2023Article
- Epstein-Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma.BMC urology · 2022Article
- Prognosis and pain dissection of novel signatures in kidney renal clear cell carcinoma based on fatty acid metabolism-related genes.Frontiers in oncology · 2022Article
- Squalene deters drivers of RCC disease progression beyond VHL status.Cell biology and toxicology · 2021Article
- Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines.Oncology reports · 2021Article
- Flipside of the Coin: Iron Deficiency and Colorectal Cancer.Frontiers in immunology · 2021Review
- Differential behavior of NF-κB, IκBα and EGFR during the renal carcinogenic process in an experimental modelOncology letters · 2020Article
- Silencing of nuclear factor kappa b 1 gene expression inhibits colony formation, cell migration and invasion via the downregulation of interleukin 1 beta and matrix metallopeptidase 9 in renal cell carcinoma.Molecular biology reports · 2020Article
- MicroRNA-429 inhibits neuroblastoma cell proliferation, migration and invasion via the NF-κB pathway.Cellular & molecular biology letters · 2020Article
- Immunotherapy of Hepatocellular Carcinoma with Magnetic PD-1 Peptide-Imprinted Polymer Nanocomposite and Natural Killer Cells.Biomolecules · 2019Article
- Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.International journal of molecular sciences · 2018Review
- Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most frequently encountered tumor in the adult kidney. Many factors are known to take part in the development and progression of this tumor. Nuclear factor kappa B (NF-kappaB) is a family of the genes that includes five members acting in events such as inflammation and apoptosis. In this study, the role of NF-kappaB (p50 subunit) in ccRCC and its relation to angiogenesis and apoptosis were investigated.
methodsFormalin-fixed and paraffin embedded tissue blocks from 40 patients with ccRCC were studied. Expressions of NF-kappaB (p50), VEGF, EGFR, bc1-2 and p53 were detected immunohistochemically. The relationship of NF-kappaB with these markers and clinicopathological findings were evaluated.
resultsThe expression of NF-kappaB was detected in 35 (85%), VEGF in 37 (92.5%), EGFR in 38 (95%), bc1-2 in 33 (82.5%) and p53 in 13 (32.5%) of 40 ccRCC patients. Statistical analyses revealed a significant relation between NF-kappaB expression and VEGF (p = 0.001), EGFR (p = 0.004), bc1-2 (p = 0.010) and p53 (p = 0.037). There was no significant correlation between NF-kappaB and such parameters as tumor grade, stage, age and sex.
conclusionThe results of this study indicated that in ccRCC cases NF-kappaB was associated with markers of angiogenesis and apoptosis such as VEGF, EGFR, bc1-2 and p53. In addition, the results did not only suggest a close relationship between NF-kappaB and VEGF, EGFR, bc1-2 and p53 in ccRCC, but also indicate that NF-kappaB was a potential therapeutic target in the treatment of ccRCC resistant to chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.